Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Johnson and Johnson
AstraZeneca
Harvard Business School
Mallinckrodt

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR VESANOID


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vesanoid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005825 ↗ Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Unknown status Raghu Nandan, M.D., Inc Phase 2 1998-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00006220 ↗ Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy Terminated National Cancer Institute (NCI) Phase 1/Phase 2 1999-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
NCT00006220 ↗ Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy Terminated Washington University School of Medicine Phase 1/Phase 2 1999-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
NCT00326170 ↗ Phase II 5-Azacytidine Plus VPA Plus ATRA Completed Celgene Corporation Phase 2 2005-07-01 5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS). Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the effects of 5-aza. The goal of this clinical research study is to find the highest safe dose of valproic acid (VPA) that can be given in combination with 5-azacytidine (5-aza) and all-trans retinoic acid (ATRA) in the treatment of AML and MDS. The safety and effectiveness of this combination therapy will also be studied. Additional blood and bone marrow samples will be requested. These samples will be used to evaluate the effect of the treatment on leukemic cells. In addition, any leftover blood and bone marrow samples that are collected at the start of the study and during the regularly scheduled evaluations to be sent for research studies. The research studies will examine changes in the blood and bone marrow cells that might help explain the causes of leukemia and MDS and how the combination of 5-aza, VPA, and ATRA works.
NCT00326170 ↗ Phase II 5-Azacytidine Plus VPA Plus ATRA Completed M.D. Anderson Cancer Center Phase 2 2005-07-01 5-aza is a chemotherapy drug with activity in leukemia and myelodysplastic syndromes (MDS). Researchers hope that valproic acid (VPA) and all-trans retinoic acid (ATRA)will increase the effects of 5-aza. The goal of this clinical research study is to find the highest safe dose of valproic acid (VPA) that can be given in combination with 5-azacytidine (5-aza) and all-trans retinoic acid (ATRA) in the treatment of AML and MDS. The safety and effectiveness of this combination therapy will also be studied. Additional blood and bone marrow samples will be requested. These samples will be used to evaluate the effect of the treatment on leukemic cells. In addition, any leftover blood and bone marrow samples that are collected at the start of the study and during the regularly scheduled evaluations to be sent for research studies. The research studies will examine changes in the blood and bone marrow cells that might help explain the causes of leukemia and MDS and how the combination of 5-aza, VPA, and ATRA works.
NCT00339196 ↗ 5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS Completed Assistance Publique - Hôpitaux de Paris Phase 2 2006-07-01 MULTICENTERS. Uncontrolled and open phase II study. Evaluation of the effectiveness of a treatment associating 5 Azacytidine,Valproic acid ,Retinoic Acid at subjects-reached of syndromes myelodysplasia and acute MYELOID leukaemia Hematological response at 6 months Uncontrolled prospective cohort.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vesanoid

Condition Name

Condition Name for Vesanoid
Intervention Trials
Myelodysplastic Syndrome 3
Acute Myelogenous Leukemia 3
Acute Myeloid Leukemia 2
Acute Promyelocytic Leukemia With PML-RARA 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vesanoid
Intervention Trials
Leukemia 9
Leukemia, Myeloid, Acute 7
Myelodysplastic Syndromes 6
Preleukemia 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vesanoid

Trials by Country

Trials by Country for Vesanoid
Location Trials
United States 69
Canada 6
Australia 6
New Zealand 2
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vesanoid
Location Trials
Texas 6
Ohio 3
Oregon 3
California 3
Colorado 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vesanoid

Clinical Trial Phase

Clinical Trial Phase for Vesanoid
Clinical Trial Phase Trials
Phase 3 2
Phase 2 10
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vesanoid
Clinical Trial Phase Trials
Completed 7
Recruiting 4
Active, not recruiting 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vesanoid

Sponsor Name

Sponsor Name for Vesanoid
Sponsor Trials
Celgene Corporation 4
M.D. Anderson Cancer Center 4
National Cancer Institute (NCI) 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vesanoid
Sponsor Trials
Other 34
Industry 9
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
AstraZeneca
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.